布来韦肽单药超说明书治疗HDV失代偿期Child-B肝硬化患者的安全性与疗效:真实世界病例系列
这项回顾性研究纳入德国、奥地利和意大利中心的19例HDV相关Child-Pugh B级肝硬化患者,超说明书使用布来韦肽单药治疗,中位观察41周。74%获得病毒学应答,74%丙氨酸氨基转移酶正常,42%获得联合应答;47%从Child-Pugh B改善至A,58%初始腹水患者腹水改善。结论认为应答率与代偿期肝病相似,但并非所有患者均见改善,需对照试验确认。
要点
- 19例HDV相关Child-Pugh B肝硬化患者超说明书使用布来韦肽单药,中位观察41周。
- 病毒学应答74%,丙氨酸氨基转移酶正常74%,联合应答42%。
- 47%从Child-Pugh B改善至A,58%初始腹水患者腹水改善。
核心结论
- 布来韦肽超说明书治疗失代偿期HDV肝硬化患者的病毒学和生化应答率与代偿期肝病相似。
- 肝功能和门静脉高压的替代指标观察到显著改善,但并非所有患者均见改善。
- 需要对照试验确认布来韦肽在失代偿期HDV肝硬化中的安全性和疗效。
研究设计与样本
- 回顾性研究,纳入德国、奥地利和意大利中心的19例HDV相关失代偿期肝病患者。
- 患者均为Child-Pugh B级肝硬化,47%为男性,平均年龄51岁。
- 治疗开始时中位MELD评分为12(范围9-17),中位观察期为41周。
主要发现
- 病毒学应答率为74%,丙氨酸氨基转移酶正常者为74%,联合应答率为42%。
- 从Child-Pugh B改善至A者占47%(n=9/19)。
- 初始存在腹水的患者中,58%观察到腹水量改善(n=7/12)。
- 最相关的不良事件包括自限性丙氨酸氨基转移酶升高、无症状性胆汁酸升高以及需要肝移植。
- 尽管胆汁酸升高,不良事件被认为与治疗无关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Chronic hepatitis D is the most debilitating form of viral hepatitis frequently progressing to cirrhosis and subsequent decompensation. However, the HDV entry inhibitor bulevirtide is only approved for antiviral treatment of patients with compensated disease. We aimed for the analysis of real-world data on the off-label use of bulevirtide in the setting of decompensated liver cirrhosis. APPROACH AND RESULTS: We conducted a retrospective study in patients with HDV with decompensated liver disease at German, Austrian, and Italian centers. We included 19 patients (47% male, mean age: 51 years) with liver cirrhosis Child-Pugh B. The median MELD score was 12 (range 9-17) at treatment initiation. The median observation period was 41 weeks. Virologic response was achieved in 74% and normal alanine aminotransferase was observed in 74%. The combined response was achieved by 42%. The most relevant adverse events included self-limited alanine aminotransferase flares, an asymptomatic increase in bile acids, and the need for liver transplantation. Despite bile acid increases, adverse events were considered unrelated. Clinical and laboratory improvement from Child-Pugh B to A occurred in 47% (n = 9/19). Improvements in the amount of ascites were observed in 58% of the patients initially presenting with ascites (n = 7/12). CONCLUSIONS: This report on off-label bulevirtide treatment in patients with decompensated HDV cirrhosis shows similar virologic and biochemical response rates as observed in compensated liver disease. Significant improvements were observed in surrogates of hepatic function and portal hypertension. However, this improvement was not seen in all patients. Controlled trials are needed to confirm the safety and efficacy of bulevirtide in decompensated HDV cirrhosis.
引用
- Dietz-Fricke C, Degasperi E, Jachs M, et al. Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis-A real-world case series. Hepatology. 2024. PMID: 38478755. doi:10.1097/HEP.0000000000000847
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。